ADC Therapeutics S.A. (ADCT): Price and Financial Metrics
GET POWR RATINGS... FREE!
ADCT POWR Grades
- Sentiment is the dimension where ADCT ranks best; there it ranks ahead of 74.06% of US stocks.
- ADCT's strongest trending metric is Stability; it's been moving up over the last 179 days.
- ADCT's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).
ADCT Stock Summary
- ADCT's went public 1.87 years ago, making it older than merely 4.87% of listed US stocks we're tracking.
- ADCT's price/sales ratio is 32.81; that's higher than the P/S ratio of 94.84% of US stocks.
- Revenue growth over the past 12 months for ADC Therapeutics SA comes in at 100.61%, a number that bests 91.9% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to ADC Therapeutics SA, a group of peers worth examining would be DBX, CCXI, LSCC, QLGN, and HRTX.
- Visit ADCT's SEC page to see the company's official filings. To visit the company's web site, go to www.adctherapeutics.com.
ADCT Valuation Summary
- ADCT's price/sales ratio is 559500; this is 14723584.21% higher than that of the median Healthcare stock.
- ADCT's price/earnings ratio has moved down 22.9 over the prior 16 months.
- Over the past 16 months, ADCT's EV/EBIT ratio has gone down 21.2.
Below are key valuation metrics over time for ADCT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ADCT | 2021-08-31 | 559500 | 9.2 | -39.9 | -37.4 |
| ADCT | 2021-08-30 | 552775 | 9.1 | -39.4 | -36.9 |
| ADCT | 2021-08-27 | 565625 | 9.3 | -40.3 | -37.8 |
| ADCT | 2021-08-26 | 546650 | 9.0 | -39.0 | -36.4 |
| ADCT | 2021-08-25 | 496000 | 8.1 | -35.4 | -32.7 |
| ADCT | 2021-08-24 | 485650 | 8.0 | -34.6 | -31.9 |
ADCT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ADCT has a Quality Grade of F, ranking ahead of 3.6% of graded US stocks.
- ADCT's asset turnover comes in at 0 -- ranking 440th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ADCT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0 | 0.963 | -0.339 |
| 2021-06-30 | 0 | 0.968 | -0.398 |
| 2021-03-31 | 0 | NA | -0.435 |
| 2020-12-31 | 0 | NA | -3.500 |
ADCT Stock Price Chart Interactive Chart >
ADCT Price/Volume Stats
| Current price | $7.01 | 52-week high | $32.00 |
| Prev. close | $6.45 | 52-week low | $6.18 |
| Day low | $6.18 | Volume | 370,800 |
| Day high | $7.01 | Avg. volume | 200,063 |
| 50-day MA | $12.29 | Dividend yield | N/A |
| 200-day MA | $20.06 | Market Cap | 482.92M |
ADC Therapeutics S.A. (ADCT) Company Bio
ADC Therapeutics SA is a clinical-stage biotechnology company, which develops antibody drug conjugates. Its products include Lonca, Cami and ADCT-602. Its drugs are used in treating various advanced solid tumors. The company was founded on June 6, 2011 and is headquartered in Epalinges, Switzerland.
Latest ADCT News From Around the Web
Below are the latest news stories about ADC Therapeutics SA that investors may wish to consider to help them evaluate ADCT as an investment opportunity.
ADC Therapeutics to Host Fourth Quarter and Year-End 2021 Financial Results Conference Call on March 3, 2022LAUSANNE, Switzerland, February 24, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced that it will host a conference call and live webcast on Thursday, March 3, 2022 at 8:30 a.m. ET to report financial results for the fourth quarter and year-end 2021 and provide business updat |
ADC Therapeutics Releases its Inaugural Environmental, Social and Governance ReportLAUSANNE, Switzerland, February 17, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today unveiled its first Environmental, Social and Governance (ESG) report detailing the Company’s focus on patient care and sustainable innovation. The report marks a milestone in the Company’s evolution an |
ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor PipelineLAUSANNE, Switzerland, February 08, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today will provide insight into its ADC platform and solid tumor pipeline during a live webcast from 9:00 to 11:00 a.m. EST. |
ADC Therapeutics to Participate in Guggenheim Oncology ConferenceLAUSANNE, Switzerland, February 02, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that Chris Martin, PhD, Chief Executive Officer, will participate in a fireside chat at the virtual Guggenheim Oncology Conference on Wednesday, February 9th at 9:30 a.m. EST. |
Is ADC Therapeutics (NYSE:ADCT) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says... |
ADCT Price Returns
| 1-mo | -46.20% |
| 3-mo | -53.88% |
| 6-mo | -69.31% |
| 1-year | -65.77% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -65.30% |
| 2021 | -36.89% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...